New drug VC005 tested for mild to moderate eczema in teens and adults
Tests VC005 against a placebo in teens and adults with eczema.
Plain-language title generated from the registry record
Registry title: Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 and older with mild to moderate atopic dermatitis (eczema). It tests whether VC005 works and is safe compared with a placebo.
- Age
- 12 years or older
- Sex
- All sexes can join
- Disease stage
- Atopic dermatitis (diagnosed by the Hanifin-Rajka criteria), mild to moderate
Main reasons for not taking part
- Eczema judged by the investigator to be unstable in the 2 weeks before the start (spontaneous improvement or rapid worsening)
- Lesions only on the hands or feet, with no past involvement of other typical areas such as the face or flexural areas
- Skin damage or abnormalities at the treated area that could affect the assessment (e.g. pigmentation, extensive scarring, tattoos)
- Other skin diseases that could affect the assessment (e.g. psoriasis, acne, skin cancer, generalized erythroderma, Netherton syndrome)
Read by machine on 12 November 2026.
Where in China
- Chinese Academy of Medical Sciences Hospital for Skin DiseaseNanjing, ChinaContact: qianjin luTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jiangsu vcare pharmaceutical technology co., LTD
- Trial code
- NCT07592585
- Record updated
- 7 July 2026
- Original description
A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitisRead full original descriptionShow less
Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis
Inclusion: Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF); The age requirement for signing the ICF is 12 years old or above, with no gender restrictions; During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.
Exclusion: Patients whose AD course is judged by the investigator as unstable(spontaneous improvement or rapid worsening) within 2 weeks prior to baseline; At screening and baseline, lesions are localized only to the hands or feet, with no prior history of involvement of other typical areas (such as the face or flexural areas); Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., pigmentation, extensive scarring, tattoos, etc., at the affected area); At screening and baseline, presence of skin diseases that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton syndrome, etc.